Search for: "Watson Laboratories Inc" Results 1 - 20 of 140
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
10 Jul 2019, 5:45 am by Jennifer Brand
  Congratulations to the following Fastcase 50 award recipients:   Anette Aav, Director, IT Law Programme, University of Tartu Charlotte Alexander, Director, Legal Analytics Lab; Associate Professor, Georgia State University Jason Barnwell, Assistant General Counsel, Microsoft Raymond Bayley, CEO and Co-Founder, Novus Law LLC Kim Bennett, Founder, K Bennett Law Jess Birken, Founder, Birken Law Office Michael Bommarito, CEO and Co-Founder, LexPredict; Adjunct Professor of Law, Michigan… [read post]
1 Apr 2018, 8:25 pm by Aaron Barkoff
Watson Laboratories Inc., 875 F.3d 636, for the proposition that the marketing of a generic drug with labeling that encourages infringement can be viewed as causing infringement despite the fact that the innovator company published the results of clinical studies and promoted the patented use. [read post]
1 Apr 2018, 8:25 pm by Aaron Barkoff
Watson Laboratories Inc., 875 F.3d 636, for the proposition that the marketing of a generic drug with labeling that encourages infringement can be viewed as causing infringement despite the fact that the innovator company published the results of clinical studies and promoted the patented use. [read post]
7 Dec 2017, 9:34 pm by Patent Docs
., Actavis Laboratories UT, Inc., FKA Watson Laboratories Inc., Lupin Pharmaceuticals, Inc. and Lupin Ltd., and Amneal Pharmaceuticals LLC filed... [read post]
5 Dec 2017, 12:29 pm by Overhauser Law Offices, LLC
., Actavis Laboratories UT, Inc., FKA Watson Laboratories Inc., Lupin Pharmaceuticals, Inc., and Lupin LTD infringed patent no. 8,435,944, Method and Composition for Transdermal Drug Delivery (the ‘944 patent) and 8,807,861, Spreading Implement, (the ‘861 patent), which have been issued by the US Patent Office. [read post]
22 Feb 2017, 7:44 am by Gene Quinn
The FTC’s complaint identifies an anti-competitive reverse-payment agreement between Endo and Watson Laboratories, Inc. of Corona, CA, a company which was poised to introduce a generic version of Endo’s Lidoderm lidocaine patch into the U.S. market by the middle of 2012. [read post]
8 Feb 2017, 3:09 am by Dennis Crouch
Watson Laboratories, Inc., No. 16-493 (pre-AIA, do secret sales count as prior art?) [read post]
16 Jan 2017, 5:44 pm by Dennis Crouch
Watson Laboratories, Inc., No. 16-493 (pre-AIA, do secret sales count as prior art?) [read post]
24 Nov 2016, 8:23 pm by Kate Howard
Watson Laboratories, Inc. 16-493 Issue: Whether the “on sale” bar found in Section 102(b) of the Patent Act applies only to sales or offers of sale made available to the public, as Congress, this court, and the United States have all made clear, or whether it also applies to non-public sales or offers of sale, as the U.S. [read post]
14 Nov 2016, 9:16 am by Dennis Crouch
Watson Laboratories, Inc., No. 16-493 (pre-AIA, do secret sales count as prior art?) [read post]
10 Oct 2016, 4:00 am by Karim Benyekhlef and Nicolas Vermeys
We are reminded of the wise words written by Justice Mahoney in Apple Computer, Inc. v. [read post]